ArticleCell biology and toxicology2026
Lactate Dehydrogenase B delactylation promotes gastric cancer metastasis via enhancing glutathione-mediated resistance to ferroptosis.
Article in Cell biology and toxicology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
Abstract
purposeTo elucidate the role of protein lactylation in gastric adenocarcinoma progression, focusing on lactate dehydrogenase B (LDHB) delactylation at K58 and its effects on metastasis, glutathione (GSH) metabolism, and ferroptosis resistance.
methodsQuantitative proteomics profiled lactylation in gastric adenocarcinoma versus adjacent normal tissues. Bioinformatics and Kaplan-Meier analyses assessed differentially lactylated genes and survival correlations. LDHB lactylation sites were validated via immunoprecipitation and Western blotting in lactate-stimulated cells. Functional assays evaluated LDHB-K58R (delactylation mimic) effects on proliferation, invasion, GSH levels, cystine uptake, STAT1/SLC7A11/GPX4 expression, and RSL3-induced ferroptosis in vitro. EMT markers were examined by immunofluorescence and Western blotting. In vivo lung metastasis was assessed in nude mice injected with modified AGS cells, treated with RSL3 or DMSO.
resultsProteomics identified 121 upregulated and 53 downregulated lactylation sites in tumors, with LDHB as a key differentially lactylated protein. High LDHB expression correlated with poor progression-free and disease-specific survival. LDHB was primarily lactylated at K58; K58R delactylation enhanced proliferation, colony formation, invasion, cystine uptake, and SLC7A11-dependent GSH synthesis by suppressing STAT1 and downregulating GPX4, without affecting EMT or lactate release. K58R conferred robust resistance to RSL3-induced ferroptosis, reducing lipid ROS and preserving malignant phenotypes in vitro. In vivo, K58R promoted lung metastasis and suppressed RSL3-induced ferroptosis and lipid peroxidation (4-HNE).
conclusionLDHB-K58 delactylation drives gastric cancer metastasis via SLC7A11-mediated GSH synthesis and ferroptosis resistance, suggesting therapeutic targeting of this axis for overcoming therapy resistance.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.